Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
← catalyst calendarNCT06167317 · readout ≤ 773 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
278estimated
Sites
8
Countries
Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-09 | actual | When the study began enrolling |
| Primary completion | Sep 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: GS-0201
- Drug: Sacituzumab Govitecan — also filed as IMMU-132, Trodelvy™, GS-0132
Primary outcomes
what the primary-completion date above is the date OFThe Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation
measured First dose up to 30 days post last dose (Up to approximately 109 weeks).
The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured First dose up to 30 days post last dose (Up to approximately 109 weeks).
The Incidence of Laboratory Abnormalities
measured First dose up to 30 days post last dose (Up to approximately 109 weeks).
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed